Sensei Biotherapeutics (NASDAQ:SNSE) Releases Earnings Results, Beats Expectations By $0.01 EPS

Sensei Biotherapeutics (NASDAQ:SNSE) posted its quarterly earnings data on Tuesday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01, Yahoo Finance reports.

Sensei Biotherapeutics Stock Performance

SNSE traded down $0.04 during trading on Wednesday, reaching $0.61. 11,478 shares of the company’s stock were exchanged, compared to its average volume of 132,853. Sensei Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $1.94. The company has a market capitalization of $15.35 million, a P/E ratio of -0.54 and a beta of 0.03. The company has a quick ratio of 12.07, a current ratio of 12.07 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $0.67 and a 200 day moving average price of $0.91.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Stephens reissued an “overweight” rating and set a $5.00 target price on shares of Sensei Biotherapeutics in a research note on Friday, May 24th. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a research report on Wednesday. Finally, Citigroup restated a “buy” rating and issued a $4.00 target price on shares of Sensei Biotherapeutics in a report on Monday, June 3rd.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.